London, UK, 09 August 2012: On the day Nestlé SA’s global financial results are published, Luis Cantarell, President and CEO of Nestlé Health Science, speaking at the Global Business Summit for Retail, Food and Drink, identified the UK as being a key market driving the company’s ambition to pioneer a new industry between traditional nutrition and pharmaceuticals. Science-based personalised nutrition solutions have the potential to address chronic medical conditions, such as diabetes, obesity and Alzheimer’s.
Mr Luis Cantarell, President and CEO of Nestlé Health Science commented: “At Nestlé Health Science we are transforming the relationship between food and health creating a new role for nutrition in disease prevention and management. We are discovering how specific nutrients can influence the occurrence or progression of chronic medical conditions depending on a person’s genetic profile, as well as their lifestyle and diet. This represents a step forward in our knowledge and application of nutrition. Our presence in the UK – with Vitaflo and our core HealthCare Nutrition business– is vital in helping us shape a new emerging market between traditional nutrition and pharma. Recognised for the strength of its life science economy, wealth of talent and its reputation for innovation, creativity and clinical excellence the UK is an ideal location for us to continue to accelerate the growth of our healthcare nutrition business.”
Nestlé Health Science delivered a solid performance in the first half of 2012 with double-digit growth in North America and the emerging markets. The work of the Nestlé Institute of Health Sciences is enhancing capabilities to address specific medical conditions through personalised nutritional solutions, as do acquisitions such as Vitaflo in the UK specialising in the treatment of metabolic disorders.
Trade and Investment Minister Lord Green said: “I warmly congratulate Nestlé on its expansion plans and its further commitment to its important work in health science – an excellent reflection of the UK's position at the forefront of scientific research and development. Nestlé’s investment in the UK demonstrates the strength of the British food sector, which is a world leader in innovation and supported by a world class logistics and retail distribution infrastructure. With the world's spotlight on the UK this summer, we are working hard through the British Business Embassy programme to help companies capitalise on the unique opportunity we have in 2012 to secure new trade and investment."
Nestlé Health Science recently consolidated its operation in the UK in the North West, bringing together its core HealthCare Nutrition business with the Vitaflo operation in Liverpool. This will support the business in its ambition of becoming the UK’s number one trusted nutritional advisor to healthcare professionals, caregivers and patients.
This consolidation of expertise marks another milestone in Nestlé’s programme of investment in the UK. Over the past five years Nestlé has undertaken a multi-million pound investment programme to establish its next generation of world class manufacturing facilities. The company is now committed to investing a further £500 million in the UK over the next three years.
About Nestlé Health Science
Nestlé Health Science – in conjunction with the Nestlé Institute of Health Sciences – was formed in January 2011 to spearhead the development of science-based personalised nutritional solutions. Building on its core HealthCare Nutrition business, the company has ambitions to address chronic conditions in the area of Gastrointestinal Health, Metabolic Health and Brain Health. Nestlé Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. Nestlé Health Science is a wholly owned subsidiary of Nestlé S.A., with worldwide headquarters in Lutry, Switzerland.